Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy

Jolanta Małyszko; Jacek S. Małyszko; Tomasz Hryszko; Michał Myśliwiec

doi:10.1160/TH03-04-0243

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2004; 91(03): 480-486
DOI: 10.1160/TH03-04-0243

Theme Issue Article

Schattauer GmbH

Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy

Authors

Jolanta Małyszko

¹Department of Nephrology and Transplantology, Medical University, Białystok, Poland
Jacek S. Małyszko

¹Department of Nephrology and Transplantology, Medical University, Białystok, Poland
Tomasz Hryszko

¹Department of Nephrology and Transplantology, Medical University, Białystok, Poland
Michał Myśliwiec

¹Department of Nephrology and Transplantology, Medical University, Białystok, Poland

Abstract

Summary

Patients dialyzed due to diabetic nephropathy are at a higher risk of death due to cardiovascular complications than dialyzed non-diabetic patients. Disturbances in hemostasis may play a role in the vascular complications of diabetes mellitus. It has been postulated that TAFI-thrombin activatable fibrinolysis inhibitor, which couples two opposite systems: coagulation and fibrinolysis, may be involved in the mechanism of vascular endothelial damage in diabetic patients. We assessed: TAFI and TAFIa, markers of ongoing coagulation: thrombin-antithrombin complexes, prothrombin fragments 1+2, a marker of ongoing fibrinolysis: plasmin-antiplasmin complexes in diabetic and non-diabetic patients on hemodialyses-HD, peritoneal dialysesCAPD, patietns with chronic renal failure with and without diabetic nephropathy on conservative treatment. Both groups of dialyzed diabetic patients have a higher concentration of markers of ongoing coagulation and TAFI activity when compared to dialyzed non-diabetic patients. Linear regression analysis showed that TAFI concentration was directly related to albumin in HD and CAPD patients without diabetic nephropathy, whereas TAFIa correlated with triglycerides, fibrinogen and leukocytes count in this group. When evaluated separately (HD, CAPD), significant correlations between TAFIa and triglycerides and fibrinogen were found only in diabetic CAPD patients. Multivariate analysis showed no correlation between TAFI and other parameters studied. In conclusion, elevated circulating TAFI and TAFIa might be a new link in the pathogenesis of impaired fibrinolysis in diabetic nephropathy, and thus atherosclerosis progression, particularly in CAPD patients. Hypercoagulable state observed in diabetic patients on conservative treatment and maintained on dialyses may contribute to the higher cardiovascular mortality in this population. In these patients there is also evidence of endothelial injury, and probably secondary activation of the coagulation cascade.

Keywords

TAFI - diabetic nephropathy - hemodialyses - peritoneal dialyses - endothelium

Full Text

References

References
1 Kannel W, McGee D. Diabetes and cardiovascular risk factors: The Framingham Study. Circulation 1979; 59: 8-17.
2 Kannel WB, D’Agostino RB, Wilson PWF. et al.. Diabetes, fibrinogen and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990; 120: 672-6.
3 Stamler J, Vaccaro O, Neaton JD. et al.. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention TriaI. Diabetes Care 1993; 16: 434-9.
4 Takada Y, Urano T, Watanabe I. et al.. Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus. Thromb Res 1993; 71: 405-15.
5 Kwaan H. Changes in blood coagulation, platelet function, and plasminogen-plasmin system in diabetes. Diabetes 1992; 41: 31-8.
6 Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetes patients. Diabetes 1993; 42: 1-7.
7 Christe M, Fritschi J, Lammle B. et al.. Fifteen coagulation and fibrinolysis parameters in diabetes mellitus and in patients with vasculopathy. Thromb Haemost 1984; 52: 138-43.
8 Małyszko J, Małyszko JS, Mysliwiec M. Platelet function, serotonin and serum lipids in patients with diabetic nephropathy. Pol Arch Med Wewn 1995; 94: 26-31.
9 Małyszko J, Małyszko JS, Mazerska M. et al.. Serum lipids and fibrinolysis in type II diabetes mellitus with nephropathy. Pol Arch Med Wewn 1996; 96: 324-30.
10 Almer RO, Nilsson IM. On fibrinolysis in diabetes mellitus. Acta Med Scand 1975; 198: 101-4.
11 Sagripanti A, Barsotti G. Bleeding and thrombosis in chronic uremia. Nephron 1997; 05: 125-39.
12 Llach F. Hypercoagulability, renal vein thrombosis and other thrombotic complications of nephrotic syndrome. Kidney Int 1985; 28: 429-33.
13 Viener A, Aviram M, Better OS. et al.. Enhanced in vitro platelet aggregation in hemodialysis patients. Nephron 1986; 43: 139-43.
14 Toulon P, Jacquot C, Capron L. et al.. Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing hemodialysis. Thromb Haemost 1987; 57: 263-8.
15 Małyszko J, Małyszko JS, Mysliwiec M. Comparison of hemostasis between CAPD and HD patients. Perit Dial Int 2001; 21: 158-65.
16 Nesheim M, Wang W, Boffa M. et al.. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997; 78: 386-91.
17 Bajzar L, Nesheim ME, Morser J. et al.. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998; 273: 2793-8.
18 Wang W, Boffa MB, Bajzar L. et al.. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
19 Yano Y, Kitagawa N, Gabazza EC. et al.. Increased plasma Thrombin-Activatable Fibrinolysis Inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J Clin Endocrinol Metab 2003; 88: 736-41.
20 Blann AD. Endothelial cell activation, injury, damage and dysfunction: separate entities or mutual terms?. Blood Coagul Fibrinol 2000; 11: 623-30.
21 Małyszko J, Urano T, Knofler R. et al.. Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb Res 1994; 75: 569-76.
22 Kowalski E, Kopec M, Niewiarowski S. An evaluation of the euglobulin method for determination of fibrinolysis. J Clin Pathol 1959; 12: 215-21.
23 Bajzar L. Thrombin Activatable Fibrinolysis Inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 11: 2511-6.
24 Hryszko T, Małyszko J, Małyszko JS. et al.. Patients on peritoneal dialysis but not on hemodialysis have elevated concentration and activity of Thrombin-Activatable Fibrinolysis Activity. Thromb Res 2001; 104: 233-8.
25 Hryszko T, Małyszko J, Małyszko JS. et al.. A possible role of thrombin activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients. Nephrol Dial Transplant 2001; 16: 1592-6.
26 Hori Y, Gabazza EC, Yano Y. et al.. Insulin resistance with increased circulating levels of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 660-5.
27 Yano Y, Gabazza EC, Hori Y. et al.. Association between plasma Thrombin-Activatable Fibrinolysis Inhibitor levels and activated protein C in normotensive type 2 diabetic patients. Diabetes Care 2002; 25: 1245-6.
28 Małyszko J, Suchowierska E, Małyszko JS. et al.. A comprehensive study on hemostasis in CAPD patients treated with erythropoietin. Perit Dial Int 2002; 22: 582-92.
29 Mosnier LO, Buijtenhuijs P, Marx PF. et al.. Identification of thrombin-activatable thrombin inhibitor (TAFI) in human platelets. Blood 2003; 101: 4844-6.
30 Rustom R, Leggat H, Tomura HR. et al.. Plasma thrombomodulin in renal disease: effects of renal function and proteinuria. Clin Nephrol 1998; 50: 337-41.
31 Mosnier LO, von dem Borne PA, Meijers JC. et al.. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
32 van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
33 Gresele P, Momi S, Berrettini M. et al.. Activated human protein C prevents thrombin-induced thromboembolism in mice. J Clin Invest 1998; 101: 667-76.
34 Nakamura Y, Tomura S, Tachibana K. et al.. Enhanced fibrinolytic activity during the course of hemodialysis. Clin Nephrol 1992; 38: 90-6.
35 Tomura S, Nakamura Y, Doi M. et al.. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1996; 27: 848-54.
36 Irish AB, Green FR. Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: relationship with dyslipidemia, inflammation, and factor VII gentotype. Nephrol Dial Transplant 1998; 13: 679-84.
37 Lane DA, Ireland H, Knight I. et al.. The significance of fibrinogen derivates in plasma in human renal failure. Br J Haematol 1984; 56: 251-60.
38 Ishii Y, Yano S, Kanai H. et al.. Evaluation of blood coagulation-fibrinolysis system in patients receiving chronic hemodialysis. Nephron 1996; 73: 407-12.
39 Kobayashi M, Yorioka N, Yamakido M. Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis. Nephron 1997; 76: 56-61.
40 Vaziri ND, Gonzales EC, Wang J. et al.. Blood coagulation, fibrinolytic and inhibitory protein in end-stage renal disease: effect of hemodialysis. Am J Kidney Dis 1994; 23: 828-35.
41 Vaziri ND, Shah GM, Winer RL. et al.. Coagulation cascade, fibrinolytic system, antithrombin III, protein C and protein S in patients maintained on continuous ambulatory peritoneal dialysis. Thromb Res 1989; 53: 173-80.
42 Alwakeel J, Gader Am, Hurieb S. et al.. Coagulation inhibitors and fibrinolytic parameters in patients on peritoneal dialysis and haemodialysis. Int Urol Nephrol 1996; 28: 255-61.
43 Sagripanti A, Barsotti G. Bleeding and thrombosis in chronic uremia. Nephron 1997; 75: 125-39.
44 Opatrny Jr K, Zemanova P, Mares J. et al.. Fibrinolysis defect in long-term hemodialysis patients with type 2 diabetes mellitus and its relation to metabolic disorder. Am J Nephrol 2002; 22: 429-36.
45 Babazono T, Miyamae M, Tomonaga O. et al.. Cardiovascular risk factors in diabetic patients undergoing continuous ambulatory peritoneal dialysis. Adv Perit Dial 1996; 12: 120-5.
46 Kluft C, Meijer P, Biasucci LM. et al.. Plasma levels of TAFI are elevated in patients with unstable angina pectoris (UAP) compared to stable angina pectoris but show no relationship with outcome of UAP. Thromb Haemost 1999; suppl August 1999: 784.
47 Ordonez JD, Hiatt RA, Killebrew EJ. et al.. The increased risk of coronary heart disease associated with nephritic syndrome. Kidney Int 1993; 44: 638-42.